Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials.

ABSTRACT:

Objective

To assess validity of pain and patient global scales in gout.

Methods

The authors used data from pegloticase clinical trials in chronic refractory gout to examine the validity of visual analogue scale (VAS) pain, Short-Form 36 (SF-36) bodily pain subscale and VAS patient global assessment (all scales 0-100). Convergent/divergent validity with clinical characteristics was tested by using Spearman's correlation coefficient. For discriminant ability, the authors compared the change at 6 months between placebo and pegloticase arms and calculated effect size (ES) and standardised response mean (SRM).

Results

212 patients (mean age, 55.4 years, 82% men; 73% with tophaceous gout) provided data. VAS pain was statistically significantly correlated with tender joints

SUBMITTER: Singh JA 

PROVIDER: S-EPMC4104520 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature